ALK-Abelló

Earnings Release • Jan 6, 2016

Copenhagen, 2016-01-06 17:24 CET (GLOBE NEWSWIRE) --

ALKB:DC / OMX: ALK B / AKABY / AKBLF: In response to a continuing increasing
demand, SLIT-tablet production has already been increased while ALK has
initiated a rapid expansion of its SLIT-drops production towards a doubling of
capacity by end of Q2 2016.

ALK announced today that it has revised its 2015 financial guidance upwards
following a strong increase in sales in Europe during Q4:

-- Full-year revenue in the base business is now expected to grow by
approximately 5% in local currencies (previously: 3%) when excluding a
one-off milestone payment received last year. For Q4, growth is estimated
at 9%, including a more than 40% increase in sales of GRAZAX®.
-- Full-year revenue is consequently now estimated at approximately DKK 2.57
billion (previously: around DKK 2.5 billion).
-- Full-year EBITDA before special items is now expected to be approximately
DKK 450 million (previously: approximately DKK 400 million).

The updated guidance reflects recent market developments in France where
authorities have ordered ALK’s main competitor to temporarily suspend
production and to recall certain products. ALK will publish its Annual Report
for 2015, including a detailed financial outlook for 2016 on 9 February 2016.

“ALK’s first priority is to help doctors and as many of their patients as
possible who are affected by the situation, giving them the option of
maintaining their allergy protection and safeguarding their confidence in
allergy immunotherapy. We are working hard to support continuity of supply by
offering substitute ALK products,” says Jens Bager, President and CEO of ALK.

He continues: “ALK operates a highly automated manufacturing process for its
SLIT-tablets, including GRAZAX® and ACARIZAX®, meaning that production has
already been adapted to the increased demand. At the same time, we are rapidly
increasing production of SLIT-drops at ALK’s facility in France so that it will
have double capacity by the end of Q2 2016.”

Given the unfolding situation in France, it is impossible to gauge the
potential short and long-term impact on ALK’s business. ALK will provide
further updates as the situation becomes clearer.

                             ALK-Abelló A/S

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is a world leader in allergy
immunotherapy – a treatment of the underlying cause of allergy. The company has
approximately 1,900 employees with subsidiaries, production facilities and
distributors worldwide. ALK has entered into partnership agreements with MSD
(known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and Seqirus
(previously bioCSL) to commercialise sublingual allergy immunotherapy tablets
in North America, Japan, Russia, Australia and New Zealand, respectively. The
company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen.
Find more information at www.alk.net.